Get The Daily Rip

Stocktwits Top 25 – Week 32 ๐Ÿ“ˆ

Welcome to the Stocktwits Top 25 Newsletter for Week 32 of 2022!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.ย 

Here are the Stocktwits Top 25 Lists for Week 32:

Standard and Poor's 500

ST Top 25 S&P 500

The S&P 500 Top 25 list (+7.07%) significantly outperformed the S&P 500 index (+3.26%).ย 

There were three major changes to the list this week.

Cardinal Health (+12.70%), Nielsen Holdings PLC (+19.70%), and Nucor Corporation (+4.57%) joined the list.

They replaced Northrop Grumman (+0.42%), Huntington Ingalls Industries (+1.27%), andย Jack Henry & Associates (-1.04%).

Most notably, energy stocks rebounded after last week’s selloff.

Check out how the momentum meter has performed vs. the S&P 500 index this year:


The Large-Cap Nasdaq 100

The Nasdaq 100 Top 25 list (+2.53%) performed in line the Nasdaq 100 index (+2.71%).

There were two major changes to the list this week.

Crowdstrike Holdings (+5.07%) and Paychex Inc. (+4.68%) joined the list.

They replaced Regeneron Pharmaceuticals (+2.46%) and Electronic Arts (-0.90%).

The Nasdaq 100 list generally has the least movement each week, and this week is no exception.


The Growth-Centric Russell 2000

The Russell 2000 Top 25 list (+16.48%) significantly outperformed the Russell 2000 index (+4.93%).

There were five major changes to the list this week.

Cincor Pharma (+49.64%), Karuna Therapeutics (+97.65%), Catalyst Pharmaceuticals (+24.89%), International Seaways (+14.93%), and Range Resources (+10.96%) joined the list.

They replaced Tidewater Inc. (-0.72%), CVR Energy (+1.71%), Geron Corp. (-2.89%), Value Line Inc. (-4.84%), and Mirum Pharmaceuticals (-15.08%).

Several biotechnology stocks had outsized returns, despite the broader sector index pausing its advance this week.



The Top 25 listsโ€™ Top Dawg was Karuna Therapeutics,ย which rallied 97.65%.

The clinical-stage biopharmaceuticals company reported earnings below expectations.

However, along with the release, it announced that its phase III EMERGENT-2 study on KarXT met its primary and key secondary endpoints. In addition, the company expects to receive topline data from the EMERGENT-3 study in Q1 2023 and to file a new drug application (NDA) with the FDA for KarXT as a treatment for schizophrenia in mid-2023.

The stock nearly doubled this week, so we guess that’s a sign investors are happy with the company’s overall progress. ๐Ÿคทโ€โ™‚๏ธ

$KRTX is up 109.58% YTD.

See Yโ€™all Next Week ๐Ÿค™